How should research peptides and peptide stacks be stored?

First check: identify the product

First identify the exact product before deciding how to store it. The same substance may be sold as a dry powder, a liquid after mixing or a topical cream; these are different products with different handling and contamination risks. No general temperature, time limit or rescue method can be inferred from the peptide’s name. For a general explanation, see why the route of use matters. Understand CJC-1295 with DAC, no DAC and the human studies.123

What mixing changes—and what it cannot establish

Adding liquid changes the formulation and can introduce a contamination risk. Storage claims for the unopened powder do not establish how long a mixed product remains stable or free of contamination. This guide does not provide mixing or injection instructions. If a medicine was prescribed and supplied by a licensed pharmacy, ask that pharmacy or the prescriber for product-specific directions.123

Potency, appearance and sterility are different questions

A product may look clear or unchanged yet have lost strength, contain impurities or be contaminated. Peptides can also form aggregates: groups of molecules whose presence may affect a product, depending on the formulation. A refrigerator cannot verify identity, potency or sterility, and cooling a product does not prove that earlier damage or contamination has been reversed.

Read what a certificate of analysis can and cannot establish.123

What the evidence says about individual peptides

The FDA describes potential safety concerns and limited information for certain compounded substances, including BPC-157, CJC-1295, injectable GHK-Cu and ipamorelin. These regulator concerns are not proof that every product is contaminated, nor are they storage studies. Explore BPC-157, GHK-Cu, TB-500, CJC-1295, ipamorelin and KPV. Formulation and route also change the evidence question: see BPC-157 near an injury versus elsewhere.123

Retatrutide and seller-defined stacks

Retatrutide is investigational. The FDA says it is not a component of an FDA-approved drug and cannot be used in compounding under US federal law; study materials are handled under their trial protocol, which is not a shelf life for a seller’s vial. FDA has warned that some retatrutide products sold to consumers are falsely labeled for research; their quality is unknown and they may be harmful. GLOW and KLOW are seller-defined names: ingredients and formulations can differ, so one seller’s directions do not establish another product’s stability.123

If a product arrived warm or its history is unknown

Record its name, seller or dispensing pharmacy, form, packaging, and any known temperatures and duration. Ask a pharmacist or the licensed supplier about a prescribed product. For a research-labelled or otherwise uncertain product, a seller’s reassurance alone does not establish that it is safe or appropriate for human use. Do not infer suitability from appearance or put it back in the fridge and assume it is restored.123

Taking peptides across borders

Storage, aviation security and import law are separate questions. A prescription or a seller’s willingness to ship a product does not establish permission to carry it through departure, transit and destination countries. Check the exact substance, form and quantity with the relevant authorities; see medicines across borders and the travel hub. For the separate questions about cabin baggage and screening, see medicine and airport security.1234

Connect storage to the evidence

A storage claim cannot establish that a product is safe or effective. For one example, see the BPC-157 profile, the human evidence and the border-checking guide.